Johns Hopkins University
Baltimore, Maryland, 21287, United States
NCT Number: NCT04884308
This is pilot study of the immunologic effects of intradermal Bacille Calmette-Guerin (BCG) vaccination of adults with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and healthy volunteers.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Baltimore, Maryland, 21287, United States
This single-site, open-label clinical trial to investigate the immune effects of BCG vaccination in adults with cystic fibrosis, non-cystic fibrosis bronchiectasis and healthy volunteers by measuring pre and post vaccination immune responses, BCG uptake and protection against infections, including nontuberculous mycobacteria (NTM). This study will also gather data on study feasibility, tolerability, and safety.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(CF and non-CF bronchiectasis):
Inclusion criteria
(Healthy Volunteers):
Exclusion criteria
(All arms):
Intradermal vaccination with BCG TICE
Time frame: 3 months
Change in concentration of interferon (IFN) gamma levels in blood after Bacille Calmette-Guérin (BCG) incubation relative to baseline as measured by SFUs. Spot forming units (SFU) is a measure of immune response of mononuclear cells in response to M. avium lysate. Higher values indicate a stronger immune response.
Johns Hopkins University
Other
Effects of BCG Vaccine on the Immune System of Individuals With Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis, and Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05865886
Bronchial Diseases, Bronchiectasis
Denver, Colorado, United States
View Trial DetailsNCT04574050
Anemia, Anemia, Hemolytic
London, United Kingdom
View Trial DetailsNCT04857814
Actinomycetales Infections, Bacterial Infections
Edmonton, Alberta, Canada
View Trial DetailsNCT03420209
Bronchial Diseases, Bronchiectasis
Istanbul, Turkey (Türkiye)
View Trial Details